Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: Clinical Outcomes and Patterns of Failure

Megan E Daly, Quynh Thu Le, Peter G. Maxim, Billy W. Loo, Michael J. Kaplan, Nancy J. Fischbein, Harlan Pinto, Daniel T. Chang

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Purpose: To report outcomes, failures, and toxicities in patients treated with intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma of the oropharynx. Methods And Materials: Between Aug 2001 and Oct 2007, 107 patients were treated with IMRT with curative intent at Stanford University. Twenty-two patients were treated postoperatively, and 85 were treated definitively. Concurrent platinum-based chemotherapy was administered to 86 patients (80%) and cetuximab to 8 patients (7%). The prescribed dose was 66 Gy at 2.2 Gy/fraction for definitively treated cases and 60 Gy at 2 Gy/fraction for postoperative cases. Median follow-up was 29 months among surviving patients (range, 4-105 months). Results: Eight patients had persistent disease or local-regional failure at a median of 6.5 months (range, 0-9.9 months). Six local failures occurred entirely within the high-risk clinical target volume (CTV) (one with simultaneous distant metastasis). One patient relapsed within the high- and intermediate-risk CTV. One patient had a recurrence at the junction between the IMRT and low-neck fields. Seven patients developed distant metastasis as the first site of failure. The 3-year local-regional control (LRC), freedom from distant metastasis, overall survival, and disease-free survival rates were 92%, 92%, 83%, and 81%, respectively. T stage (T4 vs. T1-T3) was predictive of poorer LRC (p = 0.001), overall survival (p = 0.001), and disease-free survival (p < 0.001) rates. Acute toxicity consisted of 58% grade 3 mucosal and 5% grade 3 skin reactions. Six patients (6%) developed grade ≥3 late complications. Conclusions: IMRT provides excellent LRC for oropharyngeal squamous cell carcinoma. Distant metastases are a major failure pattern. No marginal failures were observed.

Original languageEnglish (US)
Pages (from-to)1339-1346
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume76
Issue number5
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Oropharyngeal Neoplasms
Intensity-Modulated Radiotherapy
radiation therapy
cancer
metastasis
Therapeutics
Neoplasm Metastasis
grade
toxicity
Disease-Free Survival
Squamous Cell Carcinoma
Oropharynx
Survival
chemotherapy
Platinum
platinum
Neck
Survival Rate

Keywords

  • IMRT
  • Intensity-modulated
  • Oropharynx
  • radiotherapy
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer : Clinical Outcomes and Patterns of Failure. / Daly, Megan E; Le, Quynh Thu; Maxim, Peter G.; Loo, Billy W.; Kaplan, Michael J.; Fischbein, Nancy J.; Pinto, Harlan; Chang, Daniel T.

In: International Journal of Radiation Oncology Biology Physics, Vol. 76, No. 5, 04.2010, p. 1339-1346.

Research output: Contribution to journalArticle

Daly, Megan E ; Le, Quynh Thu ; Maxim, Peter G. ; Loo, Billy W. ; Kaplan, Michael J. ; Fischbein, Nancy J. ; Pinto, Harlan ; Chang, Daniel T. / Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer : Clinical Outcomes and Patterns of Failure. In: International Journal of Radiation Oncology Biology Physics. 2010 ; Vol. 76, No. 5. pp. 1339-1346.
@article{e1264bbfb2584b66a45b9c39928e236f,
title = "Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: Clinical Outcomes and Patterns of Failure",
abstract = "Purpose: To report outcomes, failures, and toxicities in patients treated with intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma of the oropharynx. Methods And Materials: Between Aug 2001 and Oct 2007, 107 patients were treated with IMRT with curative intent at Stanford University. Twenty-two patients were treated postoperatively, and 85 were treated definitively. Concurrent platinum-based chemotherapy was administered to 86 patients (80{\%}) and cetuximab to 8 patients (7{\%}). The prescribed dose was 66 Gy at 2.2 Gy/fraction for definitively treated cases and 60 Gy at 2 Gy/fraction for postoperative cases. Median follow-up was 29 months among surviving patients (range, 4-105 months). Results: Eight patients had persistent disease or local-regional failure at a median of 6.5 months (range, 0-9.9 months). Six local failures occurred entirely within the high-risk clinical target volume (CTV) (one with simultaneous distant metastasis). One patient relapsed within the high- and intermediate-risk CTV. One patient had a recurrence at the junction between the IMRT and low-neck fields. Seven patients developed distant metastasis as the first site of failure. The 3-year local-regional control (LRC), freedom from distant metastasis, overall survival, and disease-free survival rates were 92{\%}, 92{\%}, 83{\%}, and 81{\%}, respectively. T stage (T4 vs. T1-T3) was predictive of poorer LRC (p = 0.001), overall survival (p = 0.001), and disease-free survival (p < 0.001) rates. Acute toxicity consisted of 58{\%} grade 3 mucosal and 5{\%} grade 3 skin reactions. Six patients (6{\%}) developed grade ≥3 late complications. Conclusions: IMRT provides excellent LRC for oropharyngeal squamous cell carcinoma. Distant metastases are a major failure pattern. No marginal failures were observed.",
keywords = "IMRT, Intensity-modulated, Oropharynx, radiotherapy, Squamous cell carcinoma",
author = "Daly, {Megan E} and Le, {Quynh Thu} and Maxim, {Peter G.} and Loo, {Billy W.} and Kaplan, {Michael J.} and Fischbein, {Nancy J.} and Harlan Pinto and Chang, {Daniel T.}",
year = "2010",
month = "4",
doi = "10.1016/j.ijrobp.2009.04.006",
language = "English (US)",
volume = "76",
pages = "1339--1346",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer

T2 - Clinical Outcomes and Patterns of Failure

AU - Daly, Megan E

AU - Le, Quynh Thu

AU - Maxim, Peter G.

AU - Loo, Billy W.

AU - Kaplan, Michael J.

AU - Fischbein, Nancy J.

AU - Pinto, Harlan

AU - Chang, Daniel T.

PY - 2010/4

Y1 - 2010/4

N2 - Purpose: To report outcomes, failures, and toxicities in patients treated with intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma of the oropharynx. Methods And Materials: Between Aug 2001 and Oct 2007, 107 patients were treated with IMRT with curative intent at Stanford University. Twenty-two patients were treated postoperatively, and 85 were treated definitively. Concurrent platinum-based chemotherapy was administered to 86 patients (80%) and cetuximab to 8 patients (7%). The prescribed dose was 66 Gy at 2.2 Gy/fraction for definitively treated cases and 60 Gy at 2 Gy/fraction for postoperative cases. Median follow-up was 29 months among surviving patients (range, 4-105 months). Results: Eight patients had persistent disease or local-regional failure at a median of 6.5 months (range, 0-9.9 months). Six local failures occurred entirely within the high-risk clinical target volume (CTV) (one with simultaneous distant metastasis). One patient relapsed within the high- and intermediate-risk CTV. One patient had a recurrence at the junction between the IMRT and low-neck fields. Seven patients developed distant metastasis as the first site of failure. The 3-year local-regional control (LRC), freedom from distant metastasis, overall survival, and disease-free survival rates were 92%, 92%, 83%, and 81%, respectively. T stage (T4 vs. T1-T3) was predictive of poorer LRC (p = 0.001), overall survival (p = 0.001), and disease-free survival (p < 0.001) rates. Acute toxicity consisted of 58% grade 3 mucosal and 5% grade 3 skin reactions. Six patients (6%) developed grade ≥3 late complications. Conclusions: IMRT provides excellent LRC for oropharyngeal squamous cell carcinoma. Distant metastases are a major failure pattern. No marginal failures were observed.

AB - Purpose: To report outcomes, failures, and toxicities in patients treated with intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma of the oropharynx. Methods And Materials: Between Aug 2001 and Oct 2007, 107 patients were treated with IMRT with curative intent at Stanford University. Twenty-two patients were treated postoperatively, and 85 were treated definitively. Concurrent platinum-based chemotherapy was administered to 86 patients (80%) and cetuximab to 8 patients (7%). The prescribed dose was 66 Gy at 2.2 Gy/fraction for definitively treated cases and 60 Gy at 2 Gy/fraction for postoperative cases. Median follow-up was 29 months among surviving patients (range, 4-105 months). Results: Eight patients had persistent disease or local-regional failure at a median of 6.5 months (range, 0-9.9 months). Six local failures occurred entirely within the high-risk clinical target volume (CTV) (one with simultaneous distant metastasis). One patient relapsed within the high- and intermediate-risk CTV. One patient had a recurrence at the junction between the IMRT and low-neck fields. Seven patients developed distant metastasis as the first site of failure. The 3-year local-regional control (LRC), freedom from distant metastasis, overall survival, and disease-free survival rates were 92%, 92%, 83%, and 81%, respectively. T stage (T4 vs. T1-T3) was predictive of poorer LRC (p = 0.001), overall survival (p = 0.001), and disease-free survival (p < 0.001) rates. Acute toxicity consisted of 58% grade 3 mucosal and 5% grade 3 skin reactions. Six patients (6%) developed grade ≥3 late complications. Conclusions: IMRT provides excellent LRC for oropharyngeal squamous cell carcinoma. Distant metastases are a major failure pattern. No marginal failures were observed.

KW - IMRT

KW - Intensity-modulated

KW - Oropharynx

KW - radiotherapy

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77949549054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949549054&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.04.006

DO - 10.1016/j.ijrobp.2009.04.006

M3 - Article

C2 - 19540068

AN - SCOPUS:77949549054

VL - 76

SP - 1339

EP - 1346

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -